Skip to content

Antibe Therapeutics Inc.

TSX | ATE Healthcare
29 Aug 2023

Antibe Therapeutics Inc. Uploaded a Video
August 29, 2023

Antibe Therapeutics Inc. Executive Presentation

This is a short executive summary of Canada-based biotech company Antibe Therapeutics from Chief Operating Offer Scott Curtis.

29 Aug 2023

Antibe Therapeutics Inc. Uploaded a Video
August 29, 2023

Antibe Therapeutics Inc. Investor Presentation

This is an executive summary of Canada-based biotech company Antibe Therapeutics from Chief Operating Offer Scott Curtis, who will run you through Antibe’s slide deck.

Industries

  • Healthcare
    • Biotechnology / Drug Development

Antibe is a clinical-stage biotechnology company leveraging its proprietary hydrogen sulfide platform to develop next-generation therapies to target inflammation arising from a wide range of medical conditions. The Company’s current pipeline includes assets that seek to overcome the gastrointestinal (“GI”) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (“NSAIDs”). Antibe’s lead drug, otenaproxesul, is in clinical development as a safer alternative to opioids and today’s NSAIDs for acute pain. Antibe’s second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company’s next target is inflammatory bowel disease (“IBD”), a condition long in need of safer, more effective therapies. Learn more at antibethera.com.

Show More + Show Less -

Contact

About Us | Please read our Privacy Policy, Cookie Policy, Disclaimer and Terms and Conditions. By accessing or using the Service you agree to be bound by these Terms. © 2024 Arrowhed Business and Investment Decisions, LLC.